VEGFA and triple-negative breast carcinoma: For example, Liu and colleagues found that liraglutide treatment accelerated human triple-negative breast cancer (TNBC) cells’ progress both in vitro and in vivo through the nicotinamide adenine dinucleotide phosphate oxidase 4/reactive oxygen species/ vascular endothelial growth factor (NOX4/ROS/VEGF) signaling pathway [125].